Kleczkowska Patrycja, Smaga Irena, Filip Małgorzata, Bujalska-Zadrozny Magdalena
Department of Pharmacodynamics, Centre for Preclinical Research and Technology, Medical University of Warsaw, 1B Banacha Str, 02-097, Warsaw, Poland.
Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland.
Neurotox Res. 2016 Nov;30(4):698-714. doi: 10.1007/s12640-016-9655-z. Epub 2016 Aug 2.
Cannabinoids are still classified as illegal psychoactive drugs despite their broad and increasingly acknowledged therapeutic potential. These substances are most famous for their wide recreational use, particularly among young adults to either alter the state of consciousness, intensify pleasure induced by other psychoactive substances or as an alternative to the previously abused drugs. It is important to emphasize that cannabinoids are often taken together with a variety of medications intended for the treatment of alcohol use disorder (AUD) or alcohol withdrawal syndrome (AWS). These medications include disulfiram, acamprosate, and naltrexone. In this paper, we summarize recent advances in the knowledge of possible beneficial effects and interactions between cannabinoids and drugs commonly used for treatment of AUD and AWS either comorbid or existing as a separate disorder.
尽管大麻素具有广泛且日益得到认可的治疗潜力,但仍被归类为非法精神活性药物。这些物质因其广泛的娱乐用途而最为出名,尤其是在年轻人中,用于改变意识状态、增强其他精神活性物质带来的愉悦感或作为先前滥用药物的替代品。必须强调的是,大麻素常常与多种用于治疗酒精使用障碍(AUD)或酒精戒断综合征(AWS)的药物一起服用。这些药物包括双硫仑、阿坎酸和纳曲酮。在本文中,我们总结了关于大麻素与常用于治疗AUD和AWS(无论是合并存在还是单独存在的疾病)的药物之间可能的有益作用和相互作用的最新知识进展。